{"id":"W2283246712","doi":"10.1007/s10637-015-0313-8","title":"A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)","year":2015,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University Health Network","funders":"National Cancer Institute","keywords":"Temsirolimus; Medicine; Mucositis; Adverse effect; Pharmacology; Tolerability; Internal medicine; Nausea; Rash; Toxicity; Gastroenterology; Urology; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001051526,0.001542896,0.001704438,0.0003733439,0.000410254,0.0007615515,0.0007944571,0.001089162,0.004048474],"category_scores_gemma":[0.0006158621,0.0005026401,0.0008588617,0.0003494901,0.0007856809,0.0008686876,0.0003241285,0.002994257,0.0009109309],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000799851,"about_ca_system_score_gemma":0.001396954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009414353,"about_ca_topic_score_gemma":0.00280096,"domain_scores_codex":[0.9997367,0.0001018574,0.0000154479,0.00005342444,0.00002933197,0.00006317134],"domain_scores_gemma":[0.9995162,0.00006515217,0.00006744411,0.00003561669,0.0000250963,0.0002904446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7694704,0.07394794,0.004738585,0.0008839727,0.0009862358,0.00049699,0.0003683081,0.003231022,0.05831383,0.0004668082,0.005458552,0.08163734],"study_design_scores_gemma":[0.6114421,0.3733817,0.007157496,0.00002881718,0.0002532632,0.0004489295,0.00005715006,0.00152368,0.003134387,0.0002389164,0.002308295,0.00002518691],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933964,0.0008651234,0.0003023913,0.0004341807,0.0001068684,0.002073119,0.0009048284,0.00007744195,0.001839666],"genre_scores_gemma":[0.9896628,0.0009914618,0.001347685,0.0006401832,0.0001446207,0.002249738,0.002224229,0.00002031441,0.002718934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004048474,"threshold_uncertainty_score":0.01354349,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02692852058864713,"score_gpt":0.3128435058557544,"score_spread":0.2859149852671073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}